Regen BioPharma, Inc. (RGBP)
USD 0.05
(-12.78%)
USD 0.05
(-12.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -686.95 Thousand USD | -102.28% |
| 2022 | -339.6 Thousand USD | -69.15% |
| 2021 | -200.77 Thousand USD | 4.08% |
| 2020 | -209.31 Thousand USD | 72.34% |
| 2019 | -756.78 Thousand USD | 46.92% |
| 2018 | -1.42 Million USD | 43.22% |
| 2017 | -2.51 Million USD | 15.09% |
| 2016 | -2.95 Million USD | -49.4% |
| 2015 | -1.97 Million USD | -180.21% |
| 2014 | -706.35 Thousand USD | -120.85% |
| 2013 | -319.83 Thousand USD | 20.29% |
| 2012 | -401.25 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -122.78 Thousand USD | -107.8% |
| 2024 Q2 | -101.07 Thousand USD | 17.68% |
| 2024 Q3 | -107.97 Thousand USD | -6.82% |
| 2023 Q3 | -58.91 Thousand USD | 25.28% |
| 2023 Q1 | -463.86 Thousand USD | -374.41% |
| 2023 Q2 | -78.84 Thousand USD | 83.0% |
| 2023 FY | -686.95 Thousand USD | -102.28% |
| 2023 Q4 | -59.08 Thousand USD | -0.3% |
| 2022 Q3 | -58.91 Thousand USD | 22.99% |
| 2022 Q4 | -97.77 Thousand USD | -65.98% |
| 2022 FY | -339.6 Thousand USD | -69.15% |
| 2022 Q1 | -106.42 Thousand USD | 94.69% |
| 2022 Q2 | -76.49 Thousand USD | 28.12% |
| 2021 Q3 | 1.83 Million USD | 14231.68% |
| 2021 Q2 | -12.97 Thousand USD | 29.8% |
| 2021 FY | -200.77 Thousand USD | 4.08% |
| 2021 Q1 | -18.48 Thousand USD | 2.27% |
| 2021 Q4 | -2 Million USD | -209.24% |
| 2020 Q4 | -18.9 Thousand USD | -15.75% |
| 2020 FY | -209.31 Thousand USD | 72.34% |
| 2020 Q3 | -16.33 Thousand USD | 58.47% |
| 2020 Q2 | -39.33 Thousand USD | 70.81% |
| 2020 Q1 | -134.73 Thousand USD | 28.87% |
| 2019 Q3 | -137.72 Thousand USD | 40.33% |
| 2019 Q4 | -189.43 Thousand USD | -37.55% |
| 2019 FY | -756.78 Thousand USD | 46.92% |
| 2019 Q1 | -198.83 Thousand USD | 23.94% |
| 2019 Q2 | -230.79 Thousand USD | -16.07% |
| 2018 Q3 | -126.37 Thousand USD | 71.82% |
| 2018 Q4 | -261.4 Thousand USD | -106.85% |
| 2018 FY | -1.42 Million USD | 43.22% |
| 2018 Q1 | -879.58 Thousand USD | -28.39% |
| 2018 Q2 | -448.42 Thousand USD | 49.02% |
| 2017 Q3 | -553.05 Thousand USD | 25.18% |
| 2017 Q4 | -685.09 Thousand USD | -23.88% |
| 2017 FY | -2.51 Million USD | 15.09% |
| 2017 Q1 | -533.58 Thousand USD | 21.17% |
| 2017 Q2 | -739.15 Thousand USD | -38.53% |
| 2016 Q1 | -689.45 Thousand USD | -231.82% |
| 2016 Q2 | -719.87 Thousand USD | -4.41% |
| 2016 Q3 | -870.78 Thousand USD | -20.96% |
| 2016 FY | -2.95 Million USD | -49.4% |
| 2016 Q4 | -676.85 Thousand USD | 22.27% |
| 2015 Q2 | 621.41 Thousand USD | 191.19% |
| 2015 FY | -1.97 Million USD | -180.21% |
| 2015 Q1 | 213.4 Thousand USD | 210.8% |
| 2015 Q4 | 523.03 Thousand USD | -15.83% |
| 2015 Q3 | 621.41 Thousand USD | -0.0% |
| 2014 FY | -706.35 Thousand USD | -120.85% |
| 2014 Q1 | 185.83 Thousand USD | 124.81% |
| 2014 Q3 | -157.86 Thousand USD | 7.16% |
| 2014 Q4 | -192.6 Thousand USD | -22.01% |
| 2014 Q2 | -170.04 Thousand USD | -191.5% |
| 2013 Q1 | -91.83 Thousand USD | 0.0% |
| 2013 Q4 | 82.66 Thousand USD | 210.47% |
| 2013 Q2 | -70.5 Thousand USD | 23.23% |
| 2013 Q3 | -74.82 Thousand USD | -6.13% |
| 2013 FY | -319.83 Thousand USD | 20.29% |
| 2012 FY | -401.25 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 48.56% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 86.382% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 96.151% |
| Nascent Biotech, Inc. | -2.22 Million USD | 69.193% |
| Rebus Holdings, Inc. | -664 Thousand USD | -3.456% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.839% |
| Qrons Inc. | -643.67 Thousand USD | -6.723% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -76.335% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.762% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -65.339% |
| Skye Bioscience, Inc. | -13.67 Million USD | 94.975% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.043% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 113.977% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -162.469% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.094% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 75.901% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 55.278% |
| Mesoblast Limited | -84.14 Million USD | 99.184% |
| Marizyme, Inc. | -34.08 Million USD | 97.985% |
| Genus plc | 6.4 Million USD | 110.734% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 107.051% |
| Pharming Group N.V. | -4.87 Million USD | 85.922% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 65.419% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 26.244% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 91.773% |
| ContraFect Corporation | -56.88 Million USD | 98.792% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 84.918% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 51.002% |
| IMV Inc. | -38.67 Million USD | 98.224% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 75.028% |
| MultiCell Technologies, Inc. | -722.81 USD | -94938.807% |
| ONE Bio Corp. | 13.68 Million USD | 105.021% |
| Accustem Sciences Inc. | -3.74 Million USD | 81.664% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.835% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -42.207% |
| Q BioMed Inc. | -3.44 Million USD | 80.063% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 119.405% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 73.856% |
| Biomind Labs Inc. | -1 Million USD | 31.958% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.75% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 76.322% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 89.667% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 63.154% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2193.503% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.671% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 64.455% |
| GB Sciences, Inc. | -1.42 Million USD | 51.641% |
| Alpha Cognition Inc. | -9.7 Million USD | 92.922% |
| HST Global, Inc. | -140.9 Thousand USD | -387.52% |
| CSL Limited | 3.7 Billion USD | 100.019% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 38.933% |
| Halberd Corporation | -75.05 Thousand USD | -815.323% |
| Enzolytics Inc. | -2.14 Million USD | 68.031% |
| Agentix Corp. | -1.37 Million USD | 49.922% |
| Resverlogix Corp. | -12.74 Million USD | 94.612% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 78.318% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.838% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 34.2% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 76.47% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 56.504% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 79.825% |
| AVAX Technologies, Inc. | 6.69 Million USD | 110.264% |
| Zenith Capital Corp. | -8.94 Million USD | 92.319% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.835% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3843.229% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 72.022% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -300.532% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 65.734% |
| Kadimastem Ltd | -3.04 Million USD | 77.405% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 30.192% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 45.307% |
| BioStem Technologies, Inc. | -7.77 Million USD | 91.169% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -278.516% |
| LadRx Corporation | -3.82 Million USD | 82.034% |
| Cell Source, Inc. | -4.32 Million USD | 84.118% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -0.0% |
| NovAccess Global Inc. | -2.46 Million USD | 72.152% |
| Affymax, Inc. | -15.04 Million USD | 95.434% |
| Itoco Inc. | -919.14 Thousand USD | 25.262% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 83.792% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 38.61% |
| Mobile Lads Corp. | -554.55 Thousand USD | -23.875% |
| CytoDyn Inc. | -18.05 Million USD | 96.196% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2629.241% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -212.139% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -21.644% |
| SYBLEU INC | -149.18 Thousand USD | -360.484% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 62.179% |
| International Stem Cell Corporation | -663 Thousand USD | -3.612% |
| Bioxytran, Inc. | -3.82 Million USD | 82.018% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1204.996% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3277.335% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.106% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 57.543% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 6.643% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 77.919% |
| Neutra Corp. | -229.48 Thousand USD | -199.343% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 96.083% |
| PureTech Health plc | -146.19 Million USD | 99.53% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 96.804% |
| IXICO plc | -1.43 Million USD | 52.196% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 92.762% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.436% |
| CSL Limited | 3.81 Billion USD | 100.018% |
| Cellectis S.A. | -108.85 Million USD | 99.369% |